Overview

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an outpatient (i.e., at home) and in the clinic. Patients who successfully complete this study will be eligible to enroll into a 12 month treatment extension (CVT-301-004E) study.
Phase:
Phase 3
Details
Lead Sponsor:
Acorda Therapeutics
Treatments:
Levodopa